Results from the first North American Clinical Experience Study provides further evidence of MV140 safety and efficacy. Red Leaf Medical (RLM) announced that results from the first North American clinical evidence for MV 140, a sublingual vaccine for the prevention of recurrent urinary tract infections (rUTI) in women, were published in the Canadian Urological Association Journal (February 2024).
The Globe and Mail and CTV News recently published reports indicating that MV140, Red Leaf Medical’s sublingual vaccine for the prevention of recurrent urinary tract infections in women, is awaiting Health Canada approval. The news items explain the impact of UTIs on women’s health and how the antibiotics used to treat them are contributing to antimicrobial resistance. Read the online CTV story here and watch the video of the story that aired on their broadcast here. The Globe and Mail article was published on February 27, 2023.
Red Leaf Medical has filed a new drug submission with Health Canada for approval of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections(rUTIs) in women. The new drug submission is supported by results from a UROMUNE™ multicenter, prospective, randomized, double-blind, placebo-controlled trial. These results were recently published in the New England Journal of Medicine Evidence.
Red Leaf Medical is pleased to announce that results from a multicenter randomized placebo-controlled trial of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections in women, were published online in the New England Journal of Medicine Evidence. Data indicates that the new vaccine significantly decreases urinary tract infections and prevents recurrence in women.
Red Leaf Medical is pleased to announce the launch of a new on-demand translation service available in more than 150 languages to meet the diverse needs of its CathetersPLUS™ customers. The company also introduced new educational tools for nurses following research in support of its CathetersPLUS™ mission to improve the lives of patients who use catheters.
Through an exclusive licensing agreement, RLM is preparing to bring new vaccines to Canada to prevent recurrent urinary tract infections and recurrent respiratory tract infections. The agreement includes BACTEK™ and UROMUNE™, novel sublingual vaccines.
Red Leaf Medical is pleased to announce the Canadian launch of INSTYLAN™, a new brand of Hyaluronic Acid (HA) for bladder instillation. INSTYLAN™ is indicated to treat Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS). Typical symptoms of IC/BPS include pelvic pain, frequency, nocturia, and urgency to urinate.
A systematic review on the role of UROMUNE™ (MV140) in the prevention of rUTI (recurrent urinary tract infections) has been published. The study, led by Dr. J. Curtis Nickel (Queen's University, Canada), has taken into account published clinical data conducted with this vaccine. UROMUNE (MV140) is a sublingual vaccine developed and manufactured by INMUNOTEK.
Red Leaf Medical thanks its team of dedicated employees for helping to build a leading Canadian healthcare company specializing in the fields of urology and infectious disease. From its founding in 2009, Red Leaf Medical has worked to become a trusted partner to patients and healthcare providers offering industry leading services and patient support programs.
Red Leaf Medical, founded in 2009, is unique in its approach to the Canadian healthcare market. Charles Ko, managing director, discusses Red Leaf Medical's foundation, the significance of listening to customers' needs and how a sound domestic reputation can lead to expansive international partnerships.